Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1992 Jul;68(801):575–580. doi: 10.1136/pgmj.68.801.575

One year experience in the treatment of familial hypercholesterolaemia with simvastatin.

J Quiney 1, G F Watts 1, M Kerr-Muir 1, B Slavin 1, B Lewis 1
PMCID: PMC2399371  PMID: 1437957

Abstract

Patients with heterozygous familial hypercholesterolaemia (FH) have a substantially increased risk of atherosclerosis due to very high plasma levels of cholesterol. Recent evidence has shown that coronary heart disease in these patients may regress with lipid-lowering therapy. In this study the efficacy and safety of simvastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A, was investigated in 30 patients with FH over a period of one year. Substantial reductions in the plasma concentrations of total cholesterol (-28%), low-density lipoprotein (LDL) cholesterol (-32%), intermediate-density lipoprotein (IDL) cholesterol and apolipoprotein (apo) B (-33%) were achieved with 20 mg/day of simvastatin; there were no significant changes in triglycerides high-density lipoprotein cholesterol or apo A. In contrast to previous studies, 40 mg/day of simvastatin did not result in a further statistically significant fall in LDL cholesterol, IDL cholesterol or apo B in the group as a whole. The drug was well tolerated and no adverse clinical or laboratory events were recorded. In particular, no ophthalmological, hepatic or renal disorders were observed and there were no sleep disturbances. We conclude that simvastatin is an efficacious and safe drug to treat patients with heterozygous FH and that rarely will the dose need to be increased above 20 mg/day.

Full text

PDF
575

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ACHOR W. P., WINKELMANN R. K., PERRY H. O. Cutaneous side effects from use of triparanol (MER-29): preliminary data on ichthyosis and loss of hair. Proc Staff Meet Mayo Clin. 1961 Apr 26;36:217–228. [PubMed] [Google Scholar]
  2. Bilheimer D. W., Grundy S. M., Brown M. S., Goldstein J. L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4124–4128. doi: 10.1073/pnas.80.13.4124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  4. Deslypere J. P., Delanghe J., Vermeulen A. Proteinuria as complication of simvastatin treatment. Lancet. 1990 Dec 8;336(8728):1453–1453. doi: 10.1016/0140-6736(90)93164-k. [DOI] [PubMed] [Google Scholar]
  5. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  6. Ginsberg H. N., Le N. A., Short M. P., Ramakrishnan R., Desnick R. J. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest. 1987 Dec;80(6):1692–1697. doi: 10.1172/JCI113259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hoeg J. M., Brewer H. B., Jr 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA. 1987 Dec 25;258(24):3532–3536. [PubMed] [Google Scholar]
  8. Kane J. P., Malloy M. J., Ports T. A., Phillips N. R., Diehl J. C., Havel R. J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990 Dec 19;264(23):3007–3012. [PubMed] [Google Scholar]
  9. Kempen H. J., Glatz J. F., Gevers Leuven J. A., van der Voort H. A., Katan M. B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988 Sep;29(9):1149–1155. [PubMed] [Google Scholar]
  10. MacDonald J. S., Gerson R. J., Kornbrust D. J., Kloss M. W., Prahalada S., Berry P. H., Alberts A. W., Bokelman D. L. Preclinical evaluation of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):16J–27J. doi: 10.1016/0002-9149(88)90003-3. [DOI] [PubMed] [Google Scholar]
  11. Mol M. J., Erkelens D. W., Leuven J. A., Schouten J. A., Stalenhoef A. F. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet. 1986 Oct 25;2(8513):936–939. doi: 10.1016/s0140-6736(86)90598-2. [DOI] [PubMed] [Google Scholar]
  12. Mount J. N., Kearney E. M., Rosseneu M., Slavin B. M. Immunoturbidimetric assays for serum apolipoproteins A1 and B using Cobas Bio centrifugal analyser. J Clin Pathol. 1988 Apr;41(4):471–474. doi: 10.1136/jcp.41.4.471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mölgaard J., von Schenck H., Olsson A. G. Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia. Eur Heart J. 1988 May;9(5):541–551. doi: 10.1093/oxfordjournals.eurheartj.a062541. [DOI] [PubMed] [Google Scholar]
  14. Shaikh M., Wootton R., Nordestgaard B. G., Baskerville P., Lumley J. S., La Ville A. E., Quiney J., Lewis B. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991 May-Jun;11(3):569–577. doi: 10.1161/01.atv.11.3.569. [DOI] [PubMed] [Google Scholar]
  15. Stone N. J., Levy R. I., Fredrickson D. S., Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974 Mar;49(3):476–488. doi: 10.1161/01.cir.49.3.476. [DOI] [PubMed] [Google Scholar]
  16. Vega G. L., Krauss R. M., Grundy S. M. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med. 1990 Feb;227(2):81–94. doi: 10.1111/j.1365-2796.1990.tb00124.x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES